News headlines about NewLink Genetics (NASDAQ:NLNK) have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. NewLink Genetics earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 47.110683955238 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
NLNK has been the subject of a number of research reports. ValuEngine raised NewLink Genetics from a “strong sell” rating to a “sell” rating in a report on Saturday, June 16th. Zacks Investment Research cut NewLink Genetics from a “buy” rating to a “hold” rating in a research report on Thursday, June 7th. Stifel Nicolaus dropped their price target on NewLink Genetics from $21.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, May 4th. Finally, Cantor Fitzgerald set a $7.00 price target on NewLink Genetics and gave the stock a “hold” rating in a research report on Thursday, May 3rd. One analyst has rated the stock with a sell rating, seven have given a hold rating and one has issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $9.64.
Shares of NLNK traded down $0.08 during trading hours on Friday, hitting $3.01. 408,871 shares of the stock were exchanged, compared to its average volume of 528,227. NewLink Genetics has a 12-month low of $2.90 and a 12-month high of $19.30. The stock has a market capitalization of $114.99 million, a price-to-earnings ratio of -1.31 and a beta of 1.37.
NewLink Genetics (NASDAQ:NLNK) last issued its earnings results on Tuesday, July 31st. The biotechnology company reported ($0.47) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.59) by $0.12. The company had revenue of $2.25 million during the quarter, compared to analysts’ expectations of $5.85 million. NewLink Genetics had a negative return on equity of 53.70% and a negative net margin of 252.18%. sell-side analysts predict that NewLink Genetics will post -1.69 EPS for the current year.
In other NewLink Genetics news, Director Ernest Talarico III sold 13,806 shares of the company’s stock in a transaction on Tuesday, July 10th. The stock was sold at an average price of $4.82, for a total value of $66,544.92. Following the completion of the sale, the director now directly owns 39,365 shares in the company, valued at approximately $189,739.30. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 12.30% of the stock is owned by corporate insiders.
NewLink Genetics Company Profile
NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing NLG2103, a combination of indoximod and standard of care checkpoint inhibitors, which is in Phase II clinical trial for treating patients with advanced melanoma; and Indigo301, a combination of indoximod with a checkpoint inhibitor that is in Phase III clinical trial for treating patients with advanced unresectable or metastatic melanoma, as well as combination of indoximod with other cancer therapeutics for patients with melanoma, pancreatic cancer, pediatric brain tumors, and acute myeloid leukemia.
Featured Article: Diversification in Investing
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.